AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9815866
Drug: Aspirin 250
RxNorm normalized name: aspirin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 250 mg/d and oral anticoagulation (A+OAC group)
Trial: 2698587
Drug: Hemodilution with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemodilution with repeated venesections (total 250-1000 ml) and concomitant dextran 40 administration
Trial: 1124532
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg oral delta‐1‐(trans)‐tetrahydrocannabinol
Trial: 1124532
Drug: oral delta‐1‐(trans)‐tetrahydrocannabinol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral delta‐1‐(trans)‐tetrahydrocannabinol
Trial: 31658381
Drug: AJM300 960
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AJM300 960 mg
Trial: 31658381
Drug: AJM300 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AJM300 240 mg
Trial: 31658381
Drug: AJM300 480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AJM300 480 mg
Trial: 30691468
Drug: Umeclidinium bromide/vilanterol
RxNorm normalized name: Umeclidinium Bromide/Vilanterol Trifenatate 62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Umeclidinium bromide/vilanterol 62.5/25 mcg
Trial: 30691468
Drug: Tiotropium/olodaterol 5/5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium/olodaterol 5/5 mcg
Trial: 29544572
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus Simvastatin
Trial: 26388147
Drug: Ketamine (acute,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (acute, subanaesthetic doses)
Trial: 24320560
Drug: Fentanyl 1
RxNorm normalized name: fentanyl 1.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 1 μg/kg
Trial: 18166179
Drug: Anastrozole (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole (1 mg/d for 5 days starting on day 3 of menses; 115 patients, 243 cycles)
Trial: 18166179
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC; 100 mg/d; 101 patients, 226 cycles)
Trial: 14981835
Drug: Low-dose helical
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose helical CT with 10 mm collimation
Trial: 14981835
Drug: Low-dose helical
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose helical CT with 8 mm collimation
Trial: 14981835
Drug: Low-dose helical
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose helical CT with 5 mm collimation
Trial: 14981835
Drug: Sequential subsection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential subsection scan of chest with 50 mA and 8 mm collimation
Trial: 10099946
Drug: Detraining group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detraining group (stop normal training but continue activities of daily living)
Trial: 30927159
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg PEA
Trial: 30927159
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg PEA
Trial: 26354213
Drug: Stem Cell
RxNorm normalized name: Stem cells, apheresis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stem Cell Therapy (SCT) - infusion of 5-10 × 10^8 autologous mononuclear cells (MNC) by intra-coronary route
Trial: 26354213
Drug: Standard Medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Medical Therapy (non SCT group)
Trial: 26354213
Drug: Stem Cell
RxNorm normalized name: Stem cells, apheresis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stem Cell Therapy (SCT) with cell dose ≥ 5 × 10^8 (n=71)
Trial: 19731228
Drug: Iron sucrose
RxNorm normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron sucrose (600 mg intravenously in two divided doses, at least 24 hours apart, 14 days before surgery)
Trial: 19731228
Drug: Placebo (given
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (given intravenously in two divided doses, at least 24 hours apart, 14 days before surgery)
Trial: 11312473
Drug: Etomidate 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate 0.2 to 0.3 mg/kg (n = 10)
Trial: 9726264
Drug: Intense outpatient
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intense outpatient treatment
Trial: 1599887
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of 20 ml 0.375% bupivacaine with 1:200,000 epinephrine at a rate of 6 ml/hour during the first 24 hours postoperatively
Trial: 1599887
Drug: Bolus administration
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus administration of 20 ml 0.375% bupivacaine with 1:200,000 epinephrine at four-hour intervals
Trial: 31666259
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tryptophan and phenylalanine
Trial: 31666259
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of AAs
Trial: 28002201
Drug: TX-004HR 10
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TX-004HR 10 μg
Trial: 28002201
Drug: TX-004HR 25
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TX-004HR 25 μg
Trial: 28002201
Drug: TX-004HR 4
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TX-004HR 4 μg
Trial: 9139377
Drug: Nakayama strain
RxNorm normalized name: Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated Prefilled Syringe [Ixiaro]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nakayama strain JE vaccine
Trial: 9139377
Drug: Beijing strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beijing strain JE vaccine
Trial: 23183639
Drug: (S)-ketamine (serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (S)-ketamine (serum target 50 ng/ml)
Trial: 23183639
Drug: (S)-ketamine (serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (S)-ketamine (serum target 10 ng/ml)
Trial: 23183639
Drug: (S)-ketamine (serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (S)-ketamine (serum target 30 ng/ml)
Trial: 20077901
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health education programme and fluoride toothpaste use under parental supervision
Trial: 20077901
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health education programme
Trial: 12536735
Drug: Phosphocreatine (neoton)
RxNorm normalized name: phosphocysteamine
DrugBank: Phosphocreatine (DB13191)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphocreatine (neoton) group (group CP) - 4.0 g neoton intravenously 2 days before operation
Trial: 12536735
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (group C) - 5% G. S instead of neoton
Trial: 9434695
Drug: Cold blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold blood cardioplegia (4:1 dilution, blood/Plegisol, potassium chloride 15 mEq/L; n = 62)
Trial: 2455425
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 25 mg methotrexate
Trial: 2455425
Drug: Single intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intramuscular injection of 25 mg methotrexate
Trial: 2455425
Drug: Long-term maintenance
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term maintenance methotrexate therapy
Trial: 19465233
Drug: Fenofibrate 200
RxNorm normalized name: fenofibrate 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate 200 mg per day
Trial: 29096777
Drug: PedPRM (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PedPRM (2 mg escalated to 5 mg)
Trial: 26296794
Drug: 250 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 μg roflumilast
Trial: 26296794
Drug: 500 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 μg roflumilast
Trial: 26296794
Drug: 1000 μg
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 μg roflumilast
Trial: 19563187
Drug: Transcutaneous electrical
RxNorm normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous electrical acupoint stimulation and oral administration of placebo
Trial: 19563187
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Mosapride citrate dispersible tablets, Domperidone, and Omeprazole with placebo treatment of transcutaneous electrical acupoint stimulation
Trial: 11240871
Drug: Atropine 0.01
RxNorm normalized name: atropine 0.0194 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 0.01 mg.kg‐1
Trial: 10193218
Drug: Metoclopramide 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 0.2 mg.kg‐1
Trial: 11240871
Drug: Atropine 0.01
RxNorm normalized name: atropine 0.0194 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 0.01 mg.kg‐1 plus Metoclopramide 0.2 mg.kg‐1
Trial: 3797469
Drug: Lithium levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium levels 0.46‐0.60 mEq/l (group B)
Trial: 3797469
Drug: Lithium levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium levels 0.61‐0.75 mEq/l (group C)
Trial: 3797469
Drug: Lithium levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium levels 0.76‐0.90 mEq/l (group D)
Trial: 3797469
Drug: Lithium levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium levels 0.30‐0.45 mEq/l (group A)
Trial: 31751547
Drug: Current epilepsy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current epilepsy treatments
Trial: 31751547
Drug: Precision medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Precision medicine for improved seizure control and reduced toxicity
Trial: 29681046
Drug: Colchicine 1
RxNorm normalized name: colchicine 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 1 g/day orally for two months
Trial: 22050795
Drug: Follicular phase
RxNorm normalized name: Follicular hormone
DrugBank: Estrone (DB00655)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Follicular phase (propofol anesthesia at 1.5-2.0 μg/mL)
Trial: 22050795
Drug: Mid-late luteal
RxNorm normalized name: Nuphar lutea leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mid-late luteal phase (propofol anesthesia at 1.5-2.0 μg/mL)
Trial: 18838589
Drug: Ritonavir plus
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir plus raltegravir (400 mg raltegravir; 100 mg ritonavir every 12 h for 16 days with 400 mg raltegravir on day 14)
Trial: 18838589
Drug: Efavirenz plus
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efavirenz plus raltegravir (400 mg raltegravir; 600 mg efavirenz once daily for 14 days with 400 mg raltegravir on day 12)
Trial: 6213380
Drug: Topical benzoyl
RxNorm normalized name: benzoyl peroxide Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical benzoyl peroxide 5 percent
Trial: 6213380
Drug: Topical benzoyl
RxNorm normalized name: benzoyl peroxide Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical benzoyl peroxide 5 percent in 8 percent urea
Trial: 27795558
Drug: 6 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/m2 Gemtuzumab ozogamicin (GO)
Trial: 25792557
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (UC) with no exercise directives, monitored by monthly telephone contact.
Trial: 24461523
Drug: P. niruri
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P. niruri infusion (5 g/750 mL)
Trial: 17824581
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with clindamycin 1%-BPO 5% topical gel plus tretinoin microsphere gel 0.04%
Trial: 17824581
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with clindamycin 1%-BPO 5% topical gel plus tretinoin microsphere gel 0.1%
Trial: 17824581
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with clindamycin 1%-BPO 5% topical gel plus adapalene gel 0.1%
Trial: 9780616
Drug: Lacidipine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacidipine (4 mg/die)
Trial: 9780616
Drug: Idroclorotiazide +
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Idroclorotiazide + amiloride (50 mg every other day)
Trial: 3283632
Drug: nonselective beta‐blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nonselective beta‐blocker (timolol maleate 0.5%)
Trial: 3283632
Drug: cardioselective beta‐1‐blocking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cardioselective beta‐1‐blocking agent (betaxolol‐HCl 0.5%)
Trial: 31112706
Drug: Aloe polysaccharide
RxNorm normalized name: Aloe Polysaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aloe polysaccharide (APS) 600 mg/day
Trial: 31112706
Drug: Propolis 600
RxNorm normalized name: propolis
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propolis 600 mg/day
Trial: 31112706
Drug: Mixture of
RxNorm normalized name: OCTADECANOL (MIXTURE OF ISOMERS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixture of APS (420 mg/day) and propolis (180 mg/day)
Trial: 23656645
Drug: n-3 fatty
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 fatty acids (1 g daily)
Trial: 21245085
Drug: Nicotine replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine replacement therapy (21-mg nicotine transdermal patch)
Trial: 21245085
Drug: Placebo (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (placebo patch)
Trial: 8760987
Drug: Full angioscopic
RxNorm normalized name: Full Marks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full angioscopic (ANG) vein preparation
Trial: 1314065
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (LMWH) CY 216, 48 mg subcutaneous injection and two placebo injections per day.
Trial: 1314065
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UH), 5000 IU t.i.d.
Trial: 3882058
Drug: Bezafibrate (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate (10 to 20 mg/kg/day, twice daily)
Trial: 22512843
Drug: Gefitinib (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib (250 mg per day orally)
Trial: 18635285
Drug: gemcitabine/oxaliplatin/vinorelbine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemcitabine/oxaliplatin/vinorelbine combination
Trial: 14522634
Drug: Tacrolimus 0.1%
RxNorm normalized name: TACROLIMUS 0.1% OINT,TOP
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus 0.1% and 0.03% ointment
Trial: 1564133
Drug: Medication vial
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication vial with a digital timepiece cap (Phase I)
Trial: 1564133
Drug: Standard medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medication vial (Phase I control)
Trial: 3907314
Drug: Moricizine (ethmozine)
RxNorm normalized name: moricizine hydrochloride Oral Tablet [Ethmozine]
DrugBank: Moricizine (DB00680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moricizine (ethmozine) 10 to 12 mg/kg/day, administered every 12 hours
Trial: 3907314
Drug: Moricizine (ethmozine)
RxNorm normalized name: moricizine hydrochloride Oral Tablet [Ethmozine]
DrugBank: Moricizine (DB00680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moricizine (ethmozine) 10 to 12 mg/kg/day, administered every 8 hours
Trial: 29949175
Drug: SGLT‐2 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SGLT‐2 inhibitor in addition to routine insulin therapy
Trial: 29949175
Drug: Insulin therapy
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin therapy only
Trial: 24635550
Drug: Cocaine abstinence
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine abstinence during treatment (8 or 12 weeks)
Trial: 19553641
Drug: Olaparib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib (400 mg twice daily)
Trial: 10780808
Drug: Naltrexone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (50 mg) + Ethanol (0.5 g/kg)
Trial: 10780808
Drug: Naltrexone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (100 mg) + Ethanol (1.0 g/kg)
Trial: 10780808
Drug: Naltrexone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (50 mg) + Pentobarbital (150 mg)
Trial: 10780808
Drug: Naltrexone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (100 mg) + Pentobarbital (300 mg)
Trial: 10780808
Drug: Pentobarbital (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentobarbital (0 mg)
Trial: 1719716
Drug: Modified cholera
RxNorm normalized name: Modified Cholera toxin B subunit
DrugBank: Modified Cholera toxin B subunit (DB18557)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified cholera chemical vaccine (choleragen‐toxoid + O‐antigens Inaba and Ogawa)
Trial: 1719716
Drug: Commercial batch
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercial batch of monovalent cholera vaccine (choleragen‐toxoid + O‐antigen Inaba)
Trial: 23354911
Drug: Osteopathic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic treatment (5 treatment sessions)
Trial: 16788707
Drug: Magnesium (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium (300 mg/day)
Trial: 12182509
Drug: Patient education
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient education about the nature, causes, prevalence and treatment of depression
Trial: 8542859
Drug: Saline (Control)
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline (Control) 3 mL
Trial: 2013674
Drug: 4 mol/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mol/L fraction
Trial: 2013674
Drug: 1 mol/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mol/L fraction
Trial: 2013674
Drug: 1 mol/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mol/L and H2O fractions
Trial: 7032226
Drug: Single bedtime
RxNorm normalized name: Buckley's Bedtime Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single bedtime dose of chlorpromazine (300 mg)
Trial: 7032226
Drug: Divided doses
RxNorm normalized name: Aluminum Zirconium Trichlorohydrex Gly 20 g in 100 g TOPICAL STICK [Dividends]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Divided doses of chlorpromazine (100 mg, thrice daily)
Trial: 23958332
Drug: Brief Social
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief Social Behavior and Network Therapy (B‐SBNT)
Trial: 23958332
Drug: B‐SBNT and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B‐SBNT and PGS (plus routine treatment)
Trial: 18289903
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone therapy (GH) starting dose of 0.1mg/day, adjusted to maintain IGF‐I levels between 0 and 2 SDS for gender and age.
Trial: 18289903
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no GH therapy)
Trial: 14693710
Drug: Changes in
RxNorm normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Changes in 2-h postglucose insulin levels
Trial: 2390518
Drug: Oral fluorescein
RxNorm normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral fluorescein (25 mg/kg body weight)
Trial: 2390518
Drug: Oral fluorescein
RxNorm normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral fluorescein (capsules)
Trial: 2390518
Drug: Intravenous fluorescein
RxNorm normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous fluorescein